Co-founder of Uniseed investee Kinoxis, Associate Professor Michael Bowen has been awarded the Prime Minister’s Prize for New Innovators for his discovery and development of KNX100, a novel molecule that is being commercialised to treat addiction and other disorders of the brain and mind

KNX100 is now being developed to treat opioid-use disorder, which kills more people in Australia each year than car accidents.

The University of Sydney researcher leads the company’s scientific program as the Chief Scientific Officer. Kinoxis Therapeutics has attracted more than $10 million in funding, and under Associate Professor Bowen’s scientific leadership, its valuation has increased by more than 20-fold since 2018.

Associate Professor Bowen’s work is a demonstration of the innovation and all-around impact that can be achieved through research partnerships between universities, industry and government.

Acceptance speech:

 

Profesional achievements and citations:

 

associate_professor_michael_bowen_-_professional_achievements_and_citations